联环药业：公司无应披露而未披露事项

Core Viewpoint - The company announced that the Phase III clinical trial of LH-1801 is expected to unblind in the first quarter of 2026, and there are currently no undisclosed matters that need to be reported [1] Group 1 - The company is actively engaging with investors through an interactive platform, indicating transparency in communication [1] - The company emphasizes the uncertainties associated with innovative drug development, which may impact investment decisions [1] - The company will provide timely updates on any progress related to LH-1801 and encourages investors to monitor relevant announcements [1]